Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-Netherlands

NARecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

January 15, 2024

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2027

Conditions
Parkinson DiseaseProdromal StageNeurodegenerative DiseasesParkinsonian DisordersREM Sleep Behavior DisorderBasal Ganglia DiseasesCentral Nervous System DiseasesSynucleinopathiesNervous System DiseasesCerebral DisorderBrain Diseases
Interventions
BEHAVIORAL

Increase of physical activity volume and intensity with the use of a motivational smartphone application

A motivational smartphone application will be available for all participants using their own smartphone: the Slow-SPEED app. The Slow-SPEED app will motivate participants to increase the volume and intensity of their physical activity in daily life over a long period of time (2 years) based on their own baseline levels. Different treatment arms will receive different physical activity goals. The app offers participants feedback and support, that will stimulate them to reach their individual physical activity goal (i.e. incremental relative increase of step count and minutes exerting ≥ 64% of maximum heart rate reflecting MVPA relative to baseline level.).

Trial Locations (1)

6525 GA

RECRUITING

Radboud University Medical Center, Nijmegen

Sponsors
All Listed Sponsors
collaborator

Stichting ParkinsonNL

UNKNOWN

collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

Michael J. Fox Foundation for Parkinson's Research

OTHER

collaborator

Parkinson's UK

OTHER

collaborator

Cure Parkinson's

OTHER

collaborator

Edmond J. Safra Foundation

UNKNOWN

collaborator

Davis Phinney Foundation

OTHER

collaborator

Donders Centre for Cognitive Neuroimaging

OTHER

collaborator

Anne Wojcicki Foundation

UNKNOWN

collaborator

Sleep Medicine Centre Kempenhaeghe

OTHER

collaborator

Sleep Medicine Centre SEIN

UNKNOWN

collaborator

Queen Mary University of London

OTHER

collaborator

23andMe, Inc.

INDUSTRY

collaborator

Parkinsons Progression Markers Initiative (PPMI)

UNKNOWN

collaborator

Massachusetts General Hospital

OTHER

collaborator

Harvard School of Public Health (HSPH)

OTHER

collaborator

IJsfontein B.V., Netherlands

UNKNOWN

collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

Erasmus Medical Center

OTHER

collaborator

University of Illinois at Chicago

OTHER

collaborator

University of Rochester

OTHER

collaborator

University of Bristol

OTHER

collaborator

University of Plymouth

OTHER

collaborator

University of Luebeck

OTHER

collaborator

McGill University

OTHER

collaborator

University of Pittsburgh

OTHER

lead

Radboud University Medical Center

OTHER